Ethyl 2- (4-Hydroxyphenyl) -4-Methylthiazole-5-Carboxylate CAS 161797-99-5 Febuxostat Intermediate Cleanity>99.0% Factory
Ruifu Chemical Supply Febuxostat emetụtara Intermediates:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2- (3-Cyano-4-Hydroxyphenyl) -4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2- (3-Cyano-4-Isobutoxyphenyl) -4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2- (3-Formyl-4-Hydroxyphenyl) -4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2- (3-Formyl-4-Isobutoxyphenyl) -4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2- (4-Hydroxyphenyl) -4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Aha Chemical | Ethyl 2- (4-Hydroxyphenyl) -4-Methylthiazole-5-Carboxylate. |
Ụdị okwu | Febuxostat Intermediate |
Nọmba CAS | 161797-99-5 |
Nọmba CAT | RF-PI1122 |
Ọnọdụ Ahịa | Na Akụrụngwa, Ike nrụpụta 100 tọn / afọ |
Usoro ihe omimi | C13H13NO3S |
Ibu molekụla | 263.31 |
Ebe Na-agbaze | 180 ℃ |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Icha odo odo ka ọ bụrụ ntụ ntụ ọcha |
njirimara | Site na HPLC;Site na HNMR |
Ọnwụ na ihicha | <0.50% |
Ihe fọdụrụ na Ighition | <0.30% |
Otu adịghị ọcha | <0.50% |
Mgbakọta adịghị ọcha | <1.00% |
Ụzọ ịdị ọcha / nyocha | > 99.0% (nke HPLC) |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ọkara nke Febuxostat (CAS: 144060-53-7) |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri
A na-eji Ethyl 2- (4-Hydroxyphenyl) -4-Methylthiazole-5-Carboxylate (CAS: 161797-99-5) na njikọ nke Febuxostat (CAS: 144060-53-7), xanthine oxidase / xanthine dehydrogenase inhibitor.A na-eji ya maka ọgwụgwọ hyperuricemia na gout na-adịghị ala ala.40-120 mg / ụbọchị febuxostat gosipụtara na ọ dị irè n'ibelata ọkwa urate serum mgbe a na-enye ya iji jikwaa hyperuricemia na ndị ọrịa nwere gout.Achọpụtara Fabuxostat site na Teijin Pharmaceuticals ma nye ya ikike na TAP Pharmaceuticals (nke bụ akụkụ nke Takeda Pharmaceuticals ugbu a) ma kwadoro ya na US maka ọgwụgwọ hyperuricemia na ndị ọrịa nwere gout.